JP2007511216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007511216A5 JP2007511216A5 JP2006538967A JP2006538967A JP2007511216A5 JP 2007511216 A5 JP2007511216 A5 JP 2007511216A5 JP 2006538967 A JP2006538967 A JP 2006538967A JP 2006538967 A JP2006538967 A JP 2006538967A JP 2007511216 A5 JP2007511216 A5 JP 2007511216A5
- Authority
- JP
- Japan
- Prior art keywords
- herpes simplex
- simplex virus
- nucleic acid
- virus according
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700584 Simplexvirus Species 0.000 claims 43
- 108020004707 nucleic acids Proteins 0.000 claims 22
- 102000039446 nucleic acids Human genes 0.000 claims 22
- 150000007523 nucleic acids Chemical class 0.000 claims 22
- 108020004459 Small interfering RNA Proteins 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 230000001105 regulatory effect Effects 0.000 claims 8
- 230000000295 complement effect Effects 0.000 claims 7
- 108020004999 messenger RNA Proteins 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 239000003550 marker Substances 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 4
- 238000011144 upstream manufacturing Methods 0.000 claims 4
- 108700020796 Oncogene Proteins 0.000 claims 3
- 230000030279 gene silencing Effects 0.000 claims 3
- 238000013518 transcription Methods 0.000 claims 3
- 230000035897 transcription Effects 0.000 claims 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims 2
- 101150076998 ICP34.5 gene Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101150027249 RL1 gene Proteins 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 230000001276 controlling effect Effects 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 102100026982 DCN1-like protein 1 Human genes 0.000 claims 1
- 241000700589 Herpes simplex virus (type 1 / strain 17) Species 0.000 claims 1
- 101000911746 Homo sapiens DCN1-like protein 1 Proteins 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 231100000501 nonneurotoxic Toxicity 0.000 claims 1
- 230000000174 oncolytic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0326798.6A GB0326798D0 (en) | 2003-11-17 | 2003-11-17 | Methods for generating mutant virus |
| US54130804P | 2004-02-03 | 2004-02-03 | |
| PCT/GB2004/004908 WO2005049846A2 (en) | 2003-11-17 | 2004-11-17 | Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007511216A JP2007511216A (ja) | 2007-05-10 |
| JP2007511216A5 true JP2007511216A5 (enExample) | 2008-01-10 |
Family
ID=34621663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538967A Pending JP2007511216A (ja) | 2003-11-17 | 2004-11-17 | 変異ウイルス |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20070003520A1 (enExample) |
| EP (1) | EP1694852B1 (enExample) |
| JP (1) | JP2007511216A (enExample) |
| WO (1) | WO2005049846A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
| WO2005049846A2 (en) | 2003-11-17 | 2005-06-02 | Crusade Laboratories Limited | Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer |
| US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
| GB2446721B (en) * | 2007-02-16 | 2009-03-25 | Crusade Lab Ltd | Herpes simplex viruses and methods of viral replication |
| US20090117034A1 (en) | 2007-06-15 | 2009-05-07 | Nanhai Chen | Microorganisms for imaging and/or treatment of tumors |
| EP2593796A4 (en) | 2010-07-16 | 2016-07-27 | Auckland Uniservices Ltd | BACTERIAL NITROREDUCTASE ENZYMES AND METHOD THEREFOR |
| WO2012106529A1 (en) * | 2011-02-02 | 2012-08-09 | The Trustees Of Princeton University | Jagged1 as a marker and therapeutic target for breast cancer bone metastasis |
| WO2012158789A2 (en) | 2011-05-17 | 2012-11-22 | St. Jude Children's Research Hospital | Methods and compositions for inhibiting neddylation of proteins |
| US8859256B2 (en) | 2011-10-05 | 2014-10-14 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
| WO2013138522A2 (en) | 2012-03-16 | 2013-09-19 | Genelux Corporation | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
| US20130280170A1 (en) | 2012-04-20 | 2013-10-24 | Aladar A. Szalay | Imaging methods for oncolytic virus therapy |
| EP2662117A1 (en) | 2012-05-11 | 2013-11-13 | Virttu Biologics Limited | Herpes Simplex Virus for the treatment of liver cancer |
| WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| EA201700181A1 (ru) | 2014-10-14 | 2017-09-29 | Галозим, Инк. | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования |
| GB201520345D0 (en) * | 2015-11-18 | 2015-12-30 | Virttu Biolog Ltd | Herpes simplex viruses |
| AU2017250358B2 (en) | 2016-04-15 | 2023-06-01 | Alpine Immune Sciences, Inc. | ICOS ligand variant immunomodulatory proteins and uses thereof |
| IL262366B2 (en) | 2016-04-15 | 2024-07-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins and CD80 variants and their uses |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| SG11201903407XA (en) | 2016-10-20 | 2019-05-30 | Alpine Immune Sciences Inc | Secretable variant immunomodulatory proteins and engineered cell therapy |
| EP3558377A1 (en) | 2016-12-23 | 2019-10-30 | Virttu Biologics Limited | Treatment of cancer |
| EP3580341A4 (en) | 2017-02-09 | 2020-11-04 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and compositions and methods thereof |
| HUE064136T2 (hu) | 2017-03-16 | 2024-02-28 | Alpine Immune Sciences Inc | PD-L1 variáns immunmódosító fehérjék és alkalmazásuk |
| KR20250083578A (ko) | 2017-03-16 | 2025-06-10 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Cd80 변이체 면역조절 단백질 및 그의 용도 |
| US11732022B2 (en) | 2017-03-16 | 2023-08-22 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
| IL320945A (en) | 2017-10-18 | 2025-07-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins, ligands for ICOs, and compositions and methods related thereto |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN112368017A (zh) * | 2018-05-01 | 2021-02-12 | 阿尔伯特爱因斯坦医学院 | HSV-2-DELTA-gD疫苗及其生产和使用方法 |
| WO2019236633A2 (en) | 2018-06-04 | 2019-12-12 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
| US11242528B2 (en) | 2018-08-28 | 2022-02-08 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| EP3876951A1 (en) | 2018-11-06 | 2021-09-15 | Calidi Biotherapeutics, Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
| US12410402B2 (en) | 2018-11-21 | 2025-09-09 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (NK) cell subset and related compositions and methods |
| AU2019389151B2 (en) | 2018-11-30 | 2025-07-24 | Alpine Immune Sciences, Inc. | CD86 variant immunomodulatory proteins and uses thereof |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| SG11202108459QA (en) | 2019-02-27 | 2021-09-29 | Actym Therapeutics Inc | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| EP4139439A1 (en) | 2020-04-22 | 2023-03-01 | Indapta Therapeutics, Inc. | Natural killer (nk) cell compositions and methods for generating same |
| TW202241479A (zh) | 2020-12-30 | 2022-11-01 | 美商安迅生物製藥公司 | 遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法 |
| WO2025129492A1 (zh) * | 2023-12-20 | 2025-06-26 | 中国科学院深圳先进技术研究院 | 一种减毒单纯疱疹病毒在制备神经环路逆向示踪工具病毒中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965138A (en) | 1985-09-06 | 1999-10-12 | Syntro Corporation | Recombinant chimeric virus and uses thereof |
| DE68912441T2 (de) | 1988-06-24 | 1994-05-11 | British Tech Group | Nichtessentielle Geflügelpockenvirus-Regionen. |
| DE69133333T2 (de) | 1991-08-26 | 2004-07-29 | Baxter Healthcare S.A. | Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken |
| CA2167706A1 (en) | 1993-07-27 | 1995-02-09 | Nigel Fraser | Modified dna virus vectors and uses therefor |
| US6025127A (en) * | 1994-01-14 | 2000-02-15 | The Johns Hopkins University School Of Medicine | Nucleic acid mutation detection in histologic tissue |
| GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
| EP0753581A1 (en) | 1995-07-10 | 1997-01-15 | Immuno Ag | Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines |
| ZA966287B (en) | 1995-07-27 | 1998-03-09 | American Cyanamid Co | Avirulent herpetic viruses useful as tumoricidal agents and vaccines. |
| CA2234877A1 (en) | 1995-10-19 | 1997-04-24 | St. Jude Children's Research Hospital | Herpesvirus vectors and their uses |
| ATE241994T1 (de) | 1996-01-25 | 2003-06-15 | Univ Glasgow | Hsv-mutant-1716 zur behandlung von mesotheliomen |
| US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| US5922576A (en) * | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
| WO2000034497A2 (en) * | 1998-12-09 | 2000-06-15 | The General Hospital Corporation | Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors |
| WO2000052165A2 (en) | 1999-03-04 | 2000-09-08 | Corixa Corporation | Compositions and methods for breast cancer therapy and diagnosis |
| US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| ES2233349T3 (es) | 1999-08-31 | 2005-06-16 | The General Hospital Corporation | Reordenacion por promotores especificos para una celula y/o especificos para un tumor de la expresion del gen gamma 34,5 herpetico. |
| GB9930418D0 (en) | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| JP4921669B2 (ja) * | 2000-01-21 | 2012-04-25 | バイオヴェックス リミテッド | ウイルス株 |
| US20030073099A1 (en) * | 2000-04-18 | 2003-04-17 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| DK1334123T3 (da) * | 2000-11-09 | 2009-01-12 | Cenix Bioscience Gmbh | Eukaryotiske celledelingsgener og deres anvendelse til diagnose og behandling af proliferative sygdomme |
| AU2002230895A1 (en) * | 2000-12-21 | 2002-07-01 | Myriad Genetics, Inc. | Protein-protein interactions |
| EP1432799A2 (en) * | 2001-07-17 | 2004-06-30 | Anne Josephine Milner | Silencing of gene expression by sirna |
| US7348418B2 (en) * | 2002-02-08 | 2008-03-25 | Memorial Sloan-Kettering Cancer Center | Carcinoma-related genes and polypeptides and methods of use thereof |
| GB0203285D0 (en) * | 2002-02-12 | 2002-03-27 | Brown Susanne M | An herpes simplex virus complex |
| US7288529B2 (en) * | 2003-04-24 | 2007-10-30 | New York University | ALK protein tyrosine kinase, cells and methods embodying and using same |
| WO2007026146A1 (en) | 2005-08-30 | 2007-03-08 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
| WO2005049846A2 (en) | 2003-11-17 | 2005-06-02 | Crusade Laboratories Limited | Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer |
| GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| WO2007132169A1 (en) | 2006-05-11 | 2007-11-22 | Crusade Laboratories Limited | Mutant hsv, materials and methods for generation of mutant hsv |
| GB2446721B (en) | 2007-02-16 | 2009-03-25 | Crusade Lab Ltd | Herpes simplex viruses and methods of viral replication |
| GB0714578D0 (en) | 2007-07-26 | 2007-09-05 | Crusade Lab Ltd | Viruses |
-
2004
- 2004-11-17 WO PCT/GB2004/004908 patent/WO2005049846A2/en not_active Ceased
- 2004-11-17 JP JP2006538967A patent/JP2007511216A/ja active Pending
- 2004-11-17 EP EP04798619A patent/EP1694852B1/en not_active Expired - Lifetime
- 2004-11-17 US US10/579,622 patent/US20070003520A1/en not_active Abandoned
-
2009
- 2009-05-06 US US12/436,382 patent/US8530437B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007511216A5 (enExample) | ||
| US10653799B2 (en) | Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein | |
| WO2000046355B1 (en) | Telomerase reverse transcriptase transcriptional regulatory sequences | |
| JP2007511215A5 (enExample) | ||
| JP2022163182A5 (enExample) | ||
| JP5690814B2 (ja) | 抗原特異的な免疫応答を高めるための組成物及び方法 | |
| JP2010519904A5 (enExample) | ||
| CN114207134A (zh) | 工程化的mRNA序列及其用途 | |
| EP3778892A1 (en) | Novel small activating rna | |
| JPWO2020163365A5 (enExample) | ||
| JP2006507807A5 (enExample) | ||
| CA2532460A1 (en) | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof | |
| CN103484462B (zh) | Survivin启动子调控CD基因的重组腺病毒载体构建及其应用 | |
| WO2002095041A1 (en) | Virus high effectively expressing the tumor interferon and specifically reproduction in tumor cells and the use thereof | |
| JP2009535031A5 (enExample) | ||
| EP3822355A1 (en) | Anti-tumor composition | |
| KR20140018560A (ko) | Ｈｐｖ 감염과 관련된 암의 치료용 조성물 | |
| Song et al. | Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme | |
| JP2008503569A5 (enExample) | ||
| KR20030081338A (ko) | 종양 세포에서 고효율로 종양 세포 혈관형성 억제인자를발현시키는 바이러스 및 이의 용도 | |
| JPWO2020118115A5 (enExample) | ||
| CN114703186B (zh) | 肿瘤特异性启动子及其应用 | |
| WO2019000148A1 (zh) | 一种人ABCB6基因的siRNA及其应用 | |
| KR100357054B1 (ko) | 종양 특이증식 재조합 아데노바이러스 및 그를 이용하여 종양세포만을 특이적으로 형질전환시키는 방법 | |
| US20250179497A1 (en) | Use of dinucleotide repeat rnas to treat cancer |